Results from the ENCORE1 study comparing efavirenz at a reduced compared to standard dose in treatment naive patients, were presented as an oral later breaker by Rebekah Puls from the University of New South Wales, Sydney. 1
This was a double-blind, placebo-controlled, non-inferiority trial that randomised 636 patients (1:1) to efavirenz dosed at either 400 mg (n=324) or 600 mg (n=312). Tenofovir/FTC was used as the dual RTI backbone for all patients, with participants taking four pills daily because efavirenz/placebo used 200 mg capsules.
Entry criteria included CD4 50-500 cells/mm3 and viral load >1000 copies/mL. The primary endpoint was virological suppression to
At week 48, there were no significant differences by ITT analysis, with 94% vs 92% of patients having undetectable viral load in the 400 mg vs 600 mg group respectively (difference 1.8 (95% CI 2.1, +5.8), p = 0.36, NS). Very similar results were reported when stratified by baseline viral load above or below 100,000 copies/mL (all >90%). There were no differences between in the slope of viral decline, with overlapping plots at each of the week 4, 12, 24, 36 and 48 time points (p=0.35, NS).
The mean change in CD4 counts was slightly higher in the 400 mg arm (by +25 (95%CI 6, 44) cells/mm3; p=0.009).
Slightly lower rates of discontinuation were reported for the 400 mg arm (10% vs 14%) but this was not related to distribution of general side effects which were similar (approximately 47% with grade 1-2; with 2-3% grade 3-4; 7% with SAE; all p = NS).
However, significantly fewer patients discontinued treatment due to efavirenz-related side effects (rash, CNS, GI but not psychiatric) from the 400 mg arm (1.9% vs 5.8%; difference -3.9 (95%CI: -6.96, -0.95); p = 0.01) and fewer patients reported these side effects (37% vs 47%; difference -10.5% (95%CI: -18.2, -2.8); p=0.008).
The potential to use a lower efavirenz dose has been suggested for many years and this was one of the drugs suggested for use in "Micro-HAART" about a decade ago by Andrew Hill, one of the ENCORE1 investigators. 2
A more recent review article on the potential for dose optimisation for resource-limited countries is also available online. 3
It is probably also significant that the first efficacy and safety data from the randomised ENCORE1 study has only been presented as the marketing patent for efavirenz in Western countries is about to end. This drug for this study was a generic version of efavirenz produced by Mylan as the patent holder would not support this research.
These results are provocative. Rates of viral response were high in both arms, with the slightly improved tolerability in the 400 mg arm not coming at the cost of lower efficacy. The ethnic balance in the study does not suggest that the results are limited to lower weight/BMI, although this analysis was not presented. Further PK and sub-analyses are planned.
The use of four pills in this study (rather than a single tablet formulation) may make the potential cost savings important for rich as well as resource-limited countries.
No comments have been made.
|Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.|